Kazakhstan-Hong Kong partnership could spawn biotech unicorns
A dean at Nazarbayev University suggests that combining Kazakhstan's tech workforce with Hong Kong's financial network could create billion-dollar biotech startups. The country's nascent biotech sector already includes AI and digital health ventures, and with proper policies and government backing, a substantial ecosystem could emerge. He spoke at the SCMP's China Conference: Central Asia 2026 in Astana.
The proposal was made during a panel discussion at the inaugural China Conference: Central Asia 2026, held in Astana. Dean Huck-Hui Ng emphasized that combining Kazakhstan's technical expertise with Hong Kong's financial infrastructure could catalyze the growth of highly valued startups.
Kazakhstan's healthcare ambitions are already visible, as its drug regulator achieved World Health Organization certification earlier this year, a first for the region. The nation is also integrating AI into clinical diagnostics and has secured manufacturing deals from foreign pharmaceutical firms, including Chinese companies, laying groundwork for a larger ecosystem.
If this partnership materializes, it could accelerate the development of affordable medical technologies and digital health tools across Central Asia. Patients may gain earlier access to AI-assisted diagnostics, while local entrepreneurs could find new funding avenues. However, the success of such an ecosystem would likely depend on sustained regulatory alignment and political will, potentially reshaping regional healthcare dynamics if talent and capital flow freely between the two hubs.